Skip to main content
Clinical Trials/EUCTR2005-001507-19-IE
EUCTR2005-001507-19-IE
Active, not recruiting
Phase 1

Treatment with recombinant Growth Hormone in Children born Small for Gestational Age (SGA) without Catch-up Growth. - Not applicable

ational Children's Hospital & Trinity College Dublin0 sites350 target enrollmentApril 7, 2005

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Short stature in children born small for gestational age without catch up growth
Sponsor
ational Children's Hospital & Trinity College Dublin
Enrollment
350
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 7, 2005
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
ational Children's Hospital & Trinity College Dublin

Eligibility Criteria

Inclusion Criteria

  • Small for gestational age (BW \< \- 2SD below mean according to standard references)
  • Gestational age at birth more than 28 weeks
  • Short at 4 years of age (Height SDS \<\-2\.5 according to standard references)
  • Short for parental height (HSDS \> 1 SD below parental adjusted HSDS)
  • Age 4\-8 years (girls) and 4\-9 years (boys)
  • Pre\-pubertal at start of treatment (testis volume \< 4ml, breast stage 1\)
  • Height records must be available for 6 months prior to inclusion in the study
  • Height velocity SDS \< 0 during last 6 months (according to country specific references)
  • No previous growth hormone therapy.
  • Are the trial subjects under 18? yes

Exclusion Criteria

  • Known or suspected allergy to growth hormone
  • Previous participation in growth hormone trial
  • Severe mental retardation as judged by the investigation
  • Previous or active malignancy
  • Benign intracranial hypertension (present or past)
  • Diabetes mellitus
  • Growth retardation due to chronic diseases including hypertension, asthma (if on inhaled corticosteroids \>800µg/day), syndromes (like fetal alcohol syndrome) and chromosomal anomalies (except Silver Russell syndrome).
  • Psychological problems likely to lead to significant non\-compliance.

Outcomes

Primary Outcomes

Not specified

Similar Trials